Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection

被引：3

作者：

Seto, Wai-Kay ^{[1
]}

Yuen, Man-Fung ^{[1
]}

Fung, James ^{[1
]}

Lai, Ching-Lung ^{[1
]}

机构：

[1] Univ Hong Kong, Dept Med, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China

来源：

HEPATOLOGY INTERNATIONAL | 2013年 / 7卷 / 02期

关键词：

Hepatitis B; Tenofovir; Resistance; HBeAg; HBsAg; HBV DNA; VIRUS POLYMERASE MUTATIONS; ADEFOVIR DIPIVOXIL; LAMIVUDINE TREATMENT; NAIVE PATIENTS; LIVER-TRANSPLANTATION; VIROLOGICAL RESPONSE; TDF TREATMENT; THERAPY; ENTECAVIR; RESISTANCE;

D O I：

10.1007/s12072-011-9282-y

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Resistance in nucleoside/nucleotide analog (NA) therapy has always been a challenge in the management of chronic hepatitis B (CHB). Initially developed for the treatment of HIV infection, early in vitro and clinical observational studies had shown tenofovir disoproxil fumarate (TDF) to be also active against CHB. Recent data from various multicenter phase 3 and 4 clinical trials have confirmed TDF being able to achieve a high viral suppression in both NA-naive and -experienced CHB patients. There are also emerging data on the efficacy of TDF in decompensated CHB. Although there are in vitro studies identifying certain mutation loci associated with a reduced susceptibility to TDF, there have so far been no reports of virologic resistance to TDF in clinical studies. TDF has a favorable safety profile, although more long-term data would be needed. TDF has the makings of an "ideal" first-line drug for the treatment of CHB.

引用

页码：327 / 334

页数：8

共 50 条

[31] Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B [J].

Tsai, Naoky C. ;

Marcellin, Patrick ;

Buti, Maria ;

Washington, Mary Kay ;

Lee, Samuel S. ;

Chan, Sing ;

Trinh, Huy ;

Flaherty, John F. ;

Kitrinos, Kathryn M. ;

Dinh, Phillip ;

Charuworn, Prista ;

Subramanian, G. Mani ;

Gane, Edward .

DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (01) :260-268

[32] Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B [J].

Heathcote, E. Jenny ;

Marcellin, Patrick ;

Buti, Maria ;

Gane, Edward ;

De Man, Robert A. ;

Krastev, Zahary ;

Germanidis, George ;

Lee, Samuel S. ;

Flisiak, Robert ;

Kaita, Kelly ;

Manns, Michael ;

Kotzev, Iskren ;

Tchernev, Konstantin ;

Buggisch, Peter ;

Weilert, Frank ;

Kurdas, Oya Ovunc ;

Shiffman, Mitchell L. ;

Trinh, Huy ;

Gurel, Selim ;

Snow-Lampart, Andrea ;

Borroto-Esoda, Katyna ;

Mondou, Elsa ;

Anderson, Jane ;

Sorbel, Jeff ;

Rousseau, Franck .

GASTROENTEROLOGY, 2011, 140 (01) :132-143

[33] No Detectable Resistance to Tenofovir Disoproxil Fumarate After 6 Years of Therapy in Patients With Chronic Hepatitis B [J].

Kitrinos, Kathryn M. ;

Corsa, Amoreena ;

Liu, Yang ;

Flaherty, John ;

Snow-Lampart, Andrea ;

Marcellin, Patrick ;

Borroto-Esoda, Katyna ;

Miller, Michael D. .

HEPATOLOGY, 2014, 59 (02) :434-442

[34] Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir [J].

Suzuki, Fumitaka ;

Sezaki, Hitomi ;

Akuta, Norio ;

Suzuki, Yoshiyuki ;

Kawamura, Yusuke ;

Hosaka, Tetsuya ;

Kobayashi, Masahiro ;

Saitoh, Satoshi ;

Arase, Yasuji ;

Ikeda, Kenji ;

Kobayashi, Mariko ;

Watahiki, Sachiyo ;

Mineta, Rie ;

Suzuki, Yukiko ;

Kumada, Hiromitsu .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 :869-873

[35] Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B [J].

Choi, Hannah S. J. ;

Hirode, Grishma ;

Chen, Chien-Hung ;

Su, Tung-Hung ;

Seto, Wai-Kay ;

Van Hees, Stijn ;

Papatheodoridi, Margarita ;

Lens, Sabela ;

Wong, Grace L. H. ;

Brakenhoff, Sylvia M. ;

Chien, Rong-Nan ;

Feld, Jordan J. ;

Sonneveld, Milan J. ;

Chan, Henry L. Y. ;

Forns, Xavier ;

Papatheodoridis, George, V ;

Vanwolleghem, Thomas ;

Yuen, Man-Fung ;

Hsu, Yao-Chun ;

Kao, Jia-Horn ;

Cornberg, Markus ;

Hansen, Bettina E. ;

Jeng, Wen-Jue ;

Janssen, Harry L. A. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (06) :1513-1522

[36] Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir [J].

Ridruejo, Ezequiel .

WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (23) :7169-7180

[37] Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective [J].

Helen Dakin ;

Morris Sherman ;

Scott Fung ;

Carrie Fidler ;

Anthony Bentley .

PharmacoEconomics, 2011, 29 :1075-1091

[38] Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection [J].

Buti, Maria ;

Tsai, Naoky ;

Petersen, Joerg ;

Flisiak, Robert ;

Gurel, Selim ;

Krastev, Zahary ;

Schall, Raul Aguilar ;

Flaherty, John F. ;

Martins, Eduardo B. ;

Charuworn, Prista ;

Kitrinos, Kathryn M. ;

Subramanian, G. Mani ;

Gane, Edward ;

Marcellin, Patrick .

DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (05) :1457-1464

[39] Tenofovir Disoproxil FumarateIn Chronic Hepatitis B [J].

Caroline M. Perry ;

Dene Simpson .

Drugs, 2009, 69 :2245-2256

[40] Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide [J].

Hong, Hyeyeon ;

Choi, Won-Mook ;

Lee, Danbi ;

Shim, Ju Hyun ;

Kim, Kang Mo ;

Lim, Young-Suk ;

Lee, Han Chu ;

Choi, Jonggi .

CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) :49-63

← 1 2 3 4 5 →